Respiratory epithelial ion transport in patients with disseminated bronchiectasis

I. Danner*, P. Boisseau**, E. Chailleux*, D. Escande*±


ABSTRACT: The nosological limits between disseminated bronchiectasis and cystic fibrosis (CF) remain unclear. In patients with isolated congenital bilateral absence of the vas deferens, a forme fruste of the CF disease, a normal baseline nasal transepithelial potential difference (PD) but an impaired response to pharmacological interventions have been reported. The purpose of the present study was to explore ion transport in respiratory epithelium from patients with disseminated bronchiectasis.

The PD under both baseline and pharmacological interventions was investigated in 13 healthy subjects, six patients with genetically proven CF and 15 patients with disseminated bronchiectasis as confirmed by computed tomography scan.

Baseline PD was similar in the control and bronchiectasis groups but, as expected, was significantly more negative in the CF group. Patients with bronchiectasis responded to pharmacological tests (sequential perfusion with amiloride, chloride-free solution, isoprenaline and uridine triphosphate (UTP) similarly to healthy subjects. In contrast, CF patients exhibited an increased response to amiloride and an impaired response to chloride-free solution and isoprenaline.

The data show that patients with disseminated bronchiectasis exhibit normal electrophysiological properties in their nasal epithelium. Nasal transepithelial potential difference including pharmacological tests may appear a valuable diagnostic procedure for cystic fibrosis with disseminated bronchiectasis.


Cystic fibrosis (CF), the most frequent lethal autosomal recessive disorder in Caucasians, is characterized by defective electrolyte transport across secreting epithelia [1–3]. The CF gene product, cystic fibrosis transmembrane conductance regulator (CFTR), is a plasma membrane chloride channel that also acts as a regulator of heterologous ionic channels [4–6]. The CF phenotype includes disseminated bronchiectasis, pancreatic insufficiency, meconium ileus, congenital bilateral absence of the vas deferens (CBAVD), and elevated sweat chloride concentration.

Disseminated bronchiectasis is another pathological entity, first described by Laënnec in 1819 [7], which is characterized by an abnormal and permanent dilatation of the bronchial tree. Principal aetiological factors for diffuse bronchiectasis include infectious injuries during childhood, primary ciliary dyskinesia, and mucus disorders. However, the nosological limit between CF and disseminated bronchiectasis remains vague as: 1) classical CF has long been recognized as a cause of disseminated bronchiectasis [7]; 2) an increased incidence of heterozygous ΔF508 mutations in the CF gene has been repetitively reported in patients with bronchiectasis [8–11]; and 3) disseminated bronchiectasis may represent the unique clinical symptom in mild forms of genetically proven CF in adult patients [12, 13]. Similarly, the limits between isolated CBAVD and CF are also subject to discussion as: 1) patients with CBAVD have an abnormally high incidence of heterozygous mutations in the CF gene [14]; and 2) CBAVD may represent the unique clinical manifestation of a mild CF disease [15].

Measurement of sweat chloride is a classical test to diagnose CF among patients with disseminated bronchiectasis or CBAVD, although this technique occasionally provides borderline values [16, 17]. Measurement of baseline nasal transepithelial potential difference (nasal PD) is another test to diagnose CF [18, 19]. Patients with disseminated bronchiectasis or isolated CBAVD have normal nasal PD [20, 21], whereas patients with CF exhibit nasal PD hyperpolarization. However, dynamic PD recordings using pharmacological tests performed in patients with CBAVD have demonstrated a defective chloride conductance, but a normal sodium conductance [21]. It was therefore decided to explore whether nasal PD recordings in a cohort of adult patients with disseminated bronchiectasis would demonstrate dynamic anomalies unrevealed by baseline PD measurements.

Materials and methods

Potential difference measurement

Nasal PD was measured using a method described previously by KNOWLES et al. [18] and modified by ALTON et al. [22]. The reference electrode consisted of a calomel
electrode (K401 Radiometer; Radiometer Analytical SA, Villeurbanne, France) connected to a 20-G needle filled with 2.5% agar and placed subcutaneously in the forearm. The exploring electrode also consisted of a calomel electrode connected to a size 12 Foley (Laboratoire BARD SA, Trappes, France) catheter placed in the nasal cavity and perfused with a control solution containing (mM): Na⁺ 140, K⁺ 6, Mg²⁺ 1, Ca²⁺ 2, Cl⁻ 152, and glucose 10, titrated to pH 7.4 at room temperature with (2-hydroxyethyl)-piperazine-(2-ethane-sulfonic acid). Both electrodes were connected to a high impedance (10¹¹ Ω) voltmeter (A-M Systems; Pharmep, Paris, France). Prior to use, the two electrodes were placed in close contact to set the 0 mV level. The Foley catheter was placed along the floor of the nasal cavity and fixed at the most negative stable PD. In order to evaluate the response of nasal PD to perfusion with pharmacological agents, parallel perfusion lines were placed and perfused sequentially. Solution 1 was the control solution supplemented with amiloride 10⁻⁴ M. Solution 2 was a chloride-free solution with gluconate as a substitute, also supplemented with isoprenaline 10⁻⁵ M. Solution 3 was solution 2 supplemented with uridine triphosphate (UTP) and Dunn correction for non-normally distributed data was used for 10⁻³ M isoprenaline and 10⁻⁴ M UTP, and Dunnett correction for normally distributed data for chloride-free solution 3 supplemented with uridine triphosphate (UTP) 10⁻⁴ M. Perfusion with the chloride-free solution induced a junctional potential that was not compensated for.

Genotypic analysis

Mutations of CFTR were screened by the amplification refractory mutation system (ARMS). This method allowed the detection of seven common mutations: 621+1G→T, ΔF508, G542X, N1303K, G551D, 1717-1G→A, and 3659delC [23].

Subjects

Healthy subjects. Thirteen normal nonsmoking subjects (six females and seven males, age range 23–52 yrs, median age 41 yrs) were also included. Their clinical profile is summarized in table 1. Genotypic analysis of CFTR was conducted in 12/15 patients with disseminated bronchiectasis. Among these, 11 showed no mutation in the CF gene.

Patients. Six CF patients (three females and three males, age range 21–28 yrs, median age 24 yrs) were included in this study. Clinical criteria, sweat chloride concentrations and mutations are summarized in table 1. The six CF patients exhibited a typical clinical CF phenotype confirmed by genotypic analysis. Three CF patients had heart–lung transplants. A previous work demonstrated that CF patients with or without heart–lung transplant show no difference in their nasal PD [24]. An additional patient with bronchiectasis (patient No. 7) was included in the CF group for statistical analysis on the basis that the nasal PD measurement under pharmacological challenge was suggestive for CF, a diagnosis confirmed by genotypic analysis.

Fifteen patients with diffuse bronchiectasis proved on CT scan (11 females and four males, age range 17–62 yrs, median age 41 yrs) were also included. Their clinical profile is summarized in table 2. Genotypic analysis of CFTR was conducted in 12/15 patients with disseminated bronchiectasis. Among these, 11 showed no mutation in the CF gene.

Statistical analysis

All data are presented as mean±SEM and have been tested for normality by the Kolmogorov–Smirnov test. Depending on the outcome of the test, parametric or nonparametric one-way analysis of variance (ANOVA) was performed with repeated measures and non-repeated measures for data. When an overall significant difference was found, pair-wise comparisons were performed with the group of patients with bronchiectasis as the reference group. The Dunn correction for non-normally distributed data was used for 10⁻³ M isoprenaline and 10⁻⁴ M UTP, and Dunnett correction for normally distributed data for chloride-free solution 3 supplemented with uridine triphosphate (UTP) 10⁻⁴ M. Perfusion with the chloride-free solution induced a junctional potential that was not compensated for.

Table 1. – Clinical data, cystic fibrosis transmembrane conductance regulator (CFTR) genotypes and sweat chloride concentrations in cystic fibrosis patients

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age yrs</th>
<th>Mutations</th>
<th>Sweat chloride mEq·L⁻¹</th>
<th>PI/PS</th>
<th>Heart–Lung Transplantation</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>22</td>
<td>ΔF508/ΔF508</td>
<td>88</td>
<td>PI</td>
<td>No</td>
</tr>
<tr>
<td>2</td>
<td>21</td>
<td>ΔF508/3659delC</td>
<td>NA</td>
<td>PI</td>
<td>Yes</td>
</tr>
<tr>
<td>3</td>
<td>26</td>
<td>ΔF508/ΔF508</td>
<td>NA</td>
<td>PI</td>
<td>Yes</td>
</tr>
<tr>
<td>4</td>
<td>24</td>
<td>ΔF508/ΔF508</td>
<td>190</td>
<td>PI</td>
<td>No</td>
</tr>
<tr>
<td>5</td>
<td>28</td>
<td>ΔF508/ΔF508</td>
<td>NA</td>
<td>PI</td>
<td>Yes</td>
</tr>
<tr>
<td>6</td>
<td>23</td>
<td>ΔF508/ΔF508</td>
<td>NA</td>
<td>PI</td>
<td>Yes</td>
</tr>
<tr>
<td>7</td>
<td>61</td>
<td>ΔF508/L206W</td>
<td>100</td>
<td>PS</td>
<td>No</td>
</tr>
</tbody>
</table>

PI: pancreatic insufficiency; PS: pancreatic sufficiency; NA: not available.

Table 2. – Clinical data and sweat chloride concentrations in patients with disseminated bronchiectasis

<table>
<thead>
<tr>
<th>Patient No.</th>
<th>Age yrs</th>
<th>Sweat Chloride mEq·L⁻¹</th>
<th>FEV₁ L % pred</th>
<th>Pseudomonas aeruginosa</th>
</tr>
</thead>
<tbody>
<tr>
<td>7</td>
<td>61</td>
<td>100</td>
<td>0.70</td>
<td>28</td>
</tr>
<tr>
<td>8</td>
<td>52</td>
<td>24</td>
<td>1.5</td>
<td>40</td>
</tr>
<tr>
<td>9</td>
<td>42</td>
<td>48</td>
<td>0.93</td>
<td>40</td>
</tr>
<tr>
<td>10</td>
<td>49</td>
<td>NA</td>
<td>1.26</td>
<td>46</td>
</tr>
<tr>
<td>11</td>
<td>30</td>
<td>NA</td>
<td>4.71</td>
<td>115</td>
</tr>
<tr>
<td>12</td>
<td>26</td>
<td>14</td>
<td>2.12</td>
<td>63</td>
</tr>
<tr>
<td>13</td>
<td>62</td>
<td>12</td>
<td>0.54</td>
<td>21</td>
</tr>
<tr>
<td>14</td>
<td>48</td>
<td>NA</td>
<td>1.20</td>
<td>43</td>
</tr>
<tr>
<td>15</td>
<td>48</td>
<td>NA</td>
<td>NA</td>
<td>NA</td>
</tr>
<tr>
<td>16</td>
<td>32</td>
<td>12</td>
<td>0.79</td>
<td>25</td>
</tr>
<tr>
<td>17</td>
<td>25</td>
<td>9</td>
<td>2.01</td>
<td>64</td>
</tr>
<tr>
<td>18</td>
<td>51</td>
<td>NA</td>
<td>0.64</td>
<td>21</td>
</tr>
<tr>
<td>19</td>
<td>43</td>
<td>NA</td>
<td>1.64</td>
<td>49</td>
</tr>
<tr>
<td>20</td>
<td>42</td>
<td>NA</td>
<td>2.40</td>
<td>54</td>
</tr>
<tr>
<td>21</td>
<td>17</td>
<td>50</td>
<td>2.97</td>
<td>90</td>
</tr>
</tbody>
</table>

FEV₁: forced expiratory volume in one second; NA: not available. Patient 7 was also included in the cystic fibrosis group.
solution containing amiloride. The Student–Newman–Keuls correction was used for pair-wise comparisons involving a given experimental condition to the previous one. For ANOVA and pair-wise comparisons, the significance level was set at \( p < 0.05 \). All statistical analyses were performed with Sigmastat version 2.0.3 (SPSS, Germany) software.

**Results**

**Basal nasal potential difference**

Basal PD was determined in the control Hepes-buffer solution. The averaged transepithelial PD in patients with bronchiectasis was not significantly different from that recorded in healthy control subjects (fig. 1). In contrast, the basal PD in patients with CF was about two-fold more negative than in healthy volunteers or in patients with bronchiectasis. There was some degree of overlap in individual values between patients with CF and patients with bronchiectasis or healthy volunteers.

**Nasal response to amiloride**

Amiloride, a specific sodium channel blocker [25, 26], was applied locally at a final concentration of \( 10^{-4} \) M. In the three groups, the nasal PD became significantly less negative under the effects of amiloride (fig. 2). In the CF group, the decrease in nasal PD was about two-fold more pronounced than in either the healthy group or the bronchiectasis group (fig. 3). In contrast, there was no statistical difference in the response to amiloride between the control and bronchiectasis groups.

**Nasal response to chloride-free solution**

The nasal epithelium was then superfused with a chloride-free extracellular medium (solution 2). The amiloride concentration was maintained constant throughout in the superfusate so that the changes induced by chloride substitution only reflected an increase in the driving force for chloride ions. Normal subjects and bronchiectasis patients exhibited a moderate hyperpolarization of their nasal PD in response to chloride-free superfusion (fig. 2). These two groups did not differ significantly with respect to their responses to chloride-free superfusion (fig. 3). The nasal PD in patients with CF was unmodified by superfusion with chloride-free solution (figs. 2 and 3). In this respect, the difference between bronchiectasis and CF subjects reached significance (fig. 3).
activates CFTR, was perfused at a final concentration of cyclic adenosine monophosphate (cAMP) and thereafter.

Hyperpolarization as produced by UTP in the CF population was highly significant (fig. 3). In contrast, the nasal PD of control subjects, CF patients and bronchiectasis subjects. Hyperpolarization as produced by UTP in the CF population was not significantly different in amplitude from that observed in the normal or in the bronchiectasis populations.

Patient No. 7 case report

Patient No. 7 was a female aged 61 yrs who was treated for many years for disseminated bronchiectasis. Diagnosis was confirmed on chest radiograph and computed tomography scan. Sputum culture was positive for Staphylococcus aureus. Pulmonary function was altered with a forced expiratory volume in one second (FEV1) of 0.70 L (28% predicted) and a forced vital capacity (FVC) of 1.58 L (57% pred). There was no family history of CF. She had no fertility problems and presented no digestive symptoms. The diagnosis of CF was suspected because of repeated positive sweat chloride tests (100 mM). Her basal nasal PD was within normal limits (-13 mV; fig. 1). The response of the nasal PD to amiloride superfusion gave a voltage depolarization of 5 mV, i.e. within the normal range. Nasal PD did not change further under superfusion with either chloride-free solution or isoprenaline. Finally, UTP stimulation hyperpolarized the nasal PD to -17 mV. Despite her baseline PD value being close to normal, the lack of hyperpolarization produced by chloride-free solution or isoprenaline prompted the screening for mutations in her CF gene. This revealed ΔF508/L206W CFTR gene mutations.

Discussion

The present work demonstrates that nasal PD both under baseline and pharmacological interventions in patients with bronchiectasis is indistinguishable from that measured in a normal healthy population, indicating that the biochemical properties of nasal epithelia, including both the sodium and chloride transport processes, are normal in patients with bronchiectasis. Alton et al. [20] have previously demonstrated that the baseline PD in patients with bronchiectasis and in patients with Young’s syndrome is normal. Data from the present study are in line with this observation. In addition, nasal PD under pharmacological interventions is normal in patients with bronchiectasis. This is an important finding as baseline PD in CBAVD patients is normal but the response to pharmacological agents is altered.

The incidence of CF among adult patients with disseminated bronchiectasis is unknown. A prospective work investigated 38 patients with bronchiectasis with the aim of identifying possible aetiological factors using ultrastructural and functional studies of respiratory cilia, sweat test, semen analysis, and concentration of α1-protease inhibitor and immunoglobulin [27]. The diagnosis of CF was suspected in 6/38 subjects but was not confirmed by genotype analysis. Another study by Dumur et al. [8] examined 65 adults with bronchorrhea. In one of their patients, genotype analysis revealed a forme fruste of CF (sweat chloride 100 mmol·L⁻¹). Five other patients were heterozygote carriers for the ΔF508 mutation. This corresponds to an incidence of heterozygote carriers of 1/13, differing from the expected incidence of 1/25 in the general population. Another study reported five different CFTR gene mutations in a series of 16 patients with diffuse bronchiectasis [10]. Finally, Girodon et al. [11] identified 11 patients carrying CFTR mutations in a cohort of 32 patients with bronchiectasis. Taken together, these studies strongly suggest a link between CFTR mutation and bronchiectasis through an as yet unidentified mechanism.

In the case of patient No. 7 in the present study, the baseline nasal PD was within normal limits. However, the absence of significant change in the PD with isoprenaline stimulation was highly suggestive for CF, a diagnosis confirmed by genotype analysis which revealed ΔF508/
L206W mutations. The L206W mutation, located in exon 6a, is usually associated with a mild CF phenotype (bronchiectasis or CBAVD alone) or even asymptomatic presentations of CF [12, 13].

The most significant consequence of this study is that nasal transepithelial potential difference including pharmacological tests may be a valuable and rapid test to diagnose cystic fibrosis patients with predominant bronchiectasis manifestations. Further prospective studies are needed to evaluate the reliability of this test in this context.

Acknowledgements. The authors thank S. Bau for expert assistance with statistical analysis.

References